We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI Tool Rapidly Analyzes Complex Cancer Images for Personalized Treatment

By LabMedica International staff writers
Posted on 05 Dec 2025

Complex digital biopsy images that typically take an expert pathologist up to 20 minutes to assess can now be analyzed in about one minute using a new artificial intelligence (AI) tool. More...

The technology can detect cancer, identify where tumor lesions are located, and estimate the proportions of regions with varying aggressiveness. It offers a faster, more informative way to interpret tissue samples and could support more personalized treatment decisions.

The AI model, developed by researchers at the University of Cambridge (Cambridge, England, UK), was trained only on slides labeled with basic diagnostic information rather than detailed annotations. Using Superpatch-based Measurable Multiple Instance Learning, the system analyzes whole-slide images to map cancer subtypes and grade distributions, even though it was trained without region-level guidance. By capturing the heterogeneous composition of tumors, the algorithm mimics how clinicians interpret complex tissue structures.

To evaluate performance, the team tested the model on eight datasets containing 3,850 whole-slide images representing lung, kidney, ovarian, breast, stomach, and prostate cancers. The study, published in Nature Cancer, showed that the tool delivered slide-level classification accuracy comparable to or better than nine leading AI systems. It also dramatically outperformed them in estimating tumor subtype proportions and spatial distribution across tissues.

These findings suggest that the tool could streamline diagnostic workflows and expand access to advanced cancer profiling. Because it trains on inexpensive, widely available datasets, it may help overcome cost barriers associated with spatial tumor mapping. The team now plans to apply the system to predict molecular biomarkers, providing deeper insights into tumor biology and enabling more tailored treatment strategies.

“By allowing pathologists to make faster, more accurate diagnoses, we can make sure patients receive the best treatment even sooner, improving our chances of successfully treating their cancer,” said Dr. Zeyu Gao, Early Cancer Institute, University of Cambridge, developer of the algorithm.

Related Links:
University of Cambridge


New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Online QC Software
Acusera 24•7
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Repetitive Pipette
VWR® Stepper Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The findings point to the feasibility of a quick, noninvasive urine-based approach to support earlier decision-making in multiple psychiatric conditions (photo credit: Shutterstock)

Noninvasive Urine Test May Support Earlier Diagnosis of Psychiatric Disorders

Delays in diagnosing serious psychiatric conditions can leave patients without timely support and complicate treatment planning. For bipolar disorder, average time to diagnosis can exceed nine years, and... Read more

Molecular Diagnostics

view channel
Image: The schematic diagram links key MASLD, MASH, and MASLD-HCC molecular drivers to emerging multi‑omics biomarkers and therapeutic modalities, highlighting the current barriers in clinical translation and strategic solutions aimed at refined risk stratification and personalized medicine (Photo courtesy of ©Science China Press)

Emerging Biomarkers Advance Early Detection of MASLD and Liver Cancer Risk

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects about 30% of people worldwide and can advance to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.